Megan Tooley, Cardiovascular Roundtable
For those of you who missed it, I wanted to share a recent blog post by our colleagues at the Advisory Board’s Technology Insights program, “TAVR Poised for Further Market Expansion,” which provides an overview of the latest research on transcatheter valves presented at the 2013 American College of Cardiology Scientific Sessions in San Francisco.
TAVR highlights from ACC 2013
Nicole MacMillan, Cardiovascular Roundtable
Recently, a new treatment for drug-resistant hypertension known as renal denervation (RDN) has been a hot topic in the CV world. Also known as renal nerve ablation, the procedure has enormous potential to improve treatment for a large portion of the more than 68 million hypertensive patients in the United States, and may have a similarly dramatic impact for CV programs once it's approved by the FDA.
Why the hype surrounding renal denervation?
Jeffrey Rakover, Cardiovascular Roundtable
The Roundtable has received a number of questions recently regarding cath lab scheduling given today’s unpredictable volumes. We have identified several scheduling strategies that can reap rewards both in enhanced efficiency and reduced costs, addressing concerns ranging from decreasing volumes to excessive overtime costs and staff morale.
While our research finds no scheduling approach fits every institution, some promising practices are worth considering such as flexing labs and staggering staff shifts.
Below, you will find links to additional resources touching on numerous other scheduling questions — from whether to implement block scheduling to how best to delegate scheduling responsibility.
How can CV programs optimize cath lab scheduling to match demand and lower costs?